Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
  • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• the present invention relates to a series of novel 3-(imidazolyl)-2-( ⁇ -aminoalkyloxy)- propanoic acid derivatives that are inhibitors of TAFIa inhibitors and are useful in the treatment of disease.
• Sophisticated mechanisms have evolved in mammals to repair the body in the event of vascular injury and so maintain hemostasis.
• the injured blood vessel constricts to reduce the blood flow to the area, platelets aggregate to reduce the loss of blood from the area, and fibrinogen is cleaved to produce fibrin which then polymerises and forms a clot.
• This clot covers the area of vascular damage, preventing blood loss.
• Polymerised fibrin also provides a provisional matrix which enhances the subsequent repair process.
• Imbalances in the blood coagulation process are thought to be at the origin of a large and disparate number of disease conditions, which are linked by an unwanted build up of fibrin.
• the scale of fibrin build up is determined by the delicate equilibrium between the two biochemical cascades in the human body. Agents that can modulate the balance between coagulation and fibrinolysis are therefore potentially valuable in the treatment of these disease conditions.
• ⁇ -Thrombin is the final product of the blood coagulation cascade and is responsible for the conversion of fibrinogen into fibrin.
• ⁇ -thrombin also reduces the rate at which blood clots are broken down by the serine protease plasmin.
• the protein that mediates this antifibrinolytic effect of ⁇ -thrombin is TAFI (Thrombin Activatable Fibrinolysis Inhibitor).
• TAFI is a 60kDa glycoprotein found in human plasma. It is also known as procarboxypeptidase B, carboxypeptidase B, plasma carboxypeptidase B, carboxypeptidase U and carboxypeptidase R. Following initiation of the coagulation cascade it is transformed into an activated form, TAFIa, whereupon it acts upon the fibrin matrix of the developing blood clot to prevent its dissolution. TAFI circulates in normal plasma at a concentration of about 75nM in an inactive form. Thrombin converts the inactive zymogen to the active TAFI (TAFIa), a reaction that is augmented about 1250-fold by thrombomodulin.
• TAFIa cleaves both C-terminal arginine and lysine residues from the developing fibrin clot.
• tissue plasminogen activator tPA
• plasminogen which is the precursor of plasmin.
• Both tPA and plasminogen contain a structural motif called a kringle domain which binds tightly to C-terminal lysine residues. The removal of these binding sites prevents the formation of a ternary complex between tPA, plasminogen and fibrin and this inhibits the conversion of plasminogen to plasmin, thus protecting the clot from rapid degradation.
• TAFIa In the presence of a TAFIa inhibitor, TAFIa will not be able to act upon a developing fibrin clot as described above to inhibit fibrinolysis of the clot. Thus a TAFIa inhibitor should serve to enhance fibrinolysis.
• Inhibition was measured by the inhibitor's efficiency in protecting the active centre tyrosine and glutamic acid of bovine carboxypeptidase B from irreversible alkylation by bromoacetyl-D-arginine or bromoacetamidobutylguanidine. It is suggested that such inhibitors could act as bradykinin potentiators. Bovine enzymes of pancreatic origin are very different to those found in human plasma, so one would not expect inhibitors of one to inhibit the other. Moreover, such inhibitors are directed towards a very different utility. Accordingly this disclosure provides no teaching of TAFIa inhibitors or their utility.
• carboxypeptidases i.e. enzymes that cleave the C-terminal amino acid from a peptide. They may be classified as acidic, neutral or basic, depending on the type of amino acid they cleave. Basic carboxypeptidases cleave arginine, lysine and histidine.
• TAFIa is a member of a specific subset of the basic carboxypeptidases.
• the inhibitors disclosed above by Redlitz et al. and Boffa et al. are too weak, non-specific or otherwise unsuitable to be considered as suitable TAFIa inhibitors for therapeutic application. Further, whilst the role of TAFIa in clot lysis is explained, there is no suggestion that TAFIa inhibitors can be used to treat disease.
• US-A-5993815 teaches the use of a peptide that binds to the TAFI zymogen, thereby inhibiting its activation, to treat those disorders where a C-terminal lysine or arginine is cleaved from an intact peptide. Suitable disorders are arthritis, sepsis, thrombosis, strokes, deep vein thrombosis and myocardial infarctions.
• the peptide used is an antibody or a functionally active fragment. The peptide should be used in an amount to promote fibrinolysis in vivo.
• WOOO/66550 and WO00/66557 disclose broad classes of compounds useful as inhibitors of carboxypeptidase U. Inhibitors of carboxypeptidase U are postulated to facilitate fibrinolysis and thus the compounds are taught as useful in the treatment of thrombotic conditions. There is no data to support this assertion, though details of a suitable assay are given.
• WOOO/66152 discloses formulations containing a carboxypeptidase U inhibitor and a thrombin inhibitor. Suitable carboxypeptidase U inhibitors are those of WOOO/66550. The formulations are taught as primarily useful in treating thrombotic conditions.
• WO01/19836 discloses a series of phosphonate esters and analogues thereof as carboxypeptidase B inhibitors that are suitable for the treatment or prevention of thrombotic diseases.
• WO02/14285 discloses a series of ⁇ -imidazolylmethyl- ⁇ -aminocarboxylic acids and derivatives that are inhibitors of TAFIa. The compounds are considered to be potentially useful in the treatment of a number of conditions.
• the present invention discloses a further class of TAFIa inhibitors.
• the present invention provides compounds according to general formula (I)
• n is O, 1 , 2 or 3;
• R 1 is selected from (a) an optionally substituted straight chain or branched chain d- ⁇ alkyl group, (b) an optionally substituted straight chain or branched chain C 2 - 6 alkenyl group,
• Aryl is a 6-14 membered aromatic monocyclic or fused polycyclic carbocyclic group optionally substituted with one or more groups selected from R 12 , halo, OR 13 , NR 13 R 14 , NR 13 C0 2 R 12 , CO 2 R 13 , NR 13 S0 2 R 12 , CN, haloalkyl, O(haloalkyl), SR 13 , S(0)R 12 , S0 2 R 12 , OC(0)R 13 , S0 2 NR 13 R 14 , C(0)NR 13 R 14 , C 3 -7 cycloakyl, 0(C 3- cycloalkyl), R 15 and OR 15 , where R 12 is straight chain or branched chain C ⁇ -6 alkyl, R 13 and R 14 are each independently selected from hydrogen and straight chain or branched chain C ⁇ -6 alkyl, and R 15 is phenyl optionally substituted by R 12 , OR 13 , halo or haloalkyl; Aromatic heterocycle
• Halo includes fluoro, chloro, bromo and iodo groups.
• Haloalkyl includes monohaloalkyl, polyhaloalkyl and perhaloalkyl, such as 2-bromoethyl, 2,2,2-trifluoroethyl, chlorodifluoromethyl and trichloromethyl.
• alkyl includes straight chain and branched chain alkyl.
• the R 1 group and C(R 2 )(R 3 )(amino acid) group may be attached at any atom of the imidazole ring that is available to form a covalent bond, and that it is not intended that the general formula should be interpreted as limiting the R 1 group to the C 2 - and / ⁇ -positions, nor the C(R 2 )(R 3 )(amino acid) group to the C 4 - and C ⁇ -positions.
• the two groups cannot both be attached to the same atom of the imidazole ring, and that only one of the nitrogen atoms (by convention designated N 1 ) of the imidazole ring is available to form a covalent bond.
• N 1 nitrogen atoms
• the possible substitution patterns are 1 ,2-; 1 ,4-; 1 ,5-; 2,4- and 2,5-.
• Certain compounds according to formula (I) may exist in more than one tautomeric form. If the imidazole of general formula (I) is substituted at the 2- and 4-positions the 2,4-disubstituted imidazole can tautomerise to form the corresponding 2,5- disubstituted imidazole. Furthermore, where a compound includes an Aromatic heterocyle that is substituted with a hydroxyl group it may exist as the 'keto' tautomer. The tautomeric relationship between 2-hydroxypyridine and 2-pyridone is a well known example of this phenomenon. All such tautomers of compounds of formula (I), including mixtures thereof, are included in the scope of the present invention.
• the compounds of formula (I) contain one or more asymmetric carbon atoms (chiral centers) and can therefore exist in two or more optical stereoisomeric forms such as enantiomers, diastereomers and epimers. Where the compounds of formula (I) contain a carbon-carbon double bond, cis (Z) / trans (E) stereoisomerism may also occur. All such individual stereoisomers of the compounds of formula (I) and mixtures thereof, including racemates, are included in the scope of the present invention.
• Individual stereoisomers may be separated from mixtures by conventional techniques such as, for example, by fractional crystallization or by chromatography of the mixture of compounds or of a suitable salt or derivative thereof.
• individual enantiomers of the compounds of formula (I) may be prepared by resolution, such as by H.P.L.C. of the corresponding racemate using a suitable chiral support or by fractional crystallisation of the diastereoisomeric salts formed by reaction of the corresponding racemate with a suitable optically active acid or base, as appropriate.
• the individual enantiomers may also be obtained from a corresponding optically pure intermediate prepared by such a resolution method.
• the compounds of formula (I) have both acidic and basic functional groups. Therefore, in addition to the uncharged form depicted in the general formula, they may exist as internal salts (zwitterions). Furthermore, they may form pharmaceutically acceptable salts with acids and bases. Such zwitterions and salts are included within the scope of the invention.
• a pharmaceutically acceptable salt of a compound of the formula (I) may be readily prepared by mixing together solutions of a compound of the formula (I) and the desired acid or base, as appropriate.
• the salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.
• Salts may also be prepared by ion exchange, such as by equilibrating a solution of a compound of formula (I) with an appropriate ion exchange resin. Ion exchange may also be used to convert one salt form of a compound of formula (I), such as a salt with an acid or base that is not pharmaceutically acceptable, to another salt form. These methods are generally well known in the art.
• Suitable acid addition salts are formed from acids which form non-toxic salts and examples are the hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, nitrate, phosphate, hydrogen phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate, gluconate, succinate, saccharate, benzoate, methanesulphonate, ethanesulphonate, benzenesulphonate, p-toluenesulphonate and pamoate salts.
• Suitable base salts are formed from bases which form non-toxic salts and examples are the sodium, potassium, aluminium, calcium, magnesium, zinc and diethanolamine salts.
• the compounds of formula (I) may form pharmaceutically acceptable solvates (including hydrates). These solvates are also included in the scope of the present invention.
• the compounds of formula (I) may exist in one or more crystalline forms. These polymorphs, including mixtures thereof are also included within the scope of the present invention.
• Suitable prodrugs are discussed in Drugs of Today 1983, 19, 499-538 and Annual Reports in Medicinal Chemistry 1975, 70, 306-326.
• the absolute stereochemistry of the compounds of formula (I) may be as depicted in formula (IA) or formula (IB) below.
• the absolute stereochemistry at the chiral center of (IA) is designated as 'S and that of (IB) is 'R.
• the compounds of formula (IA) are particularly preferred.
• Preferred compounds of formula (I) include those where the imidazole is substituted at the C 2 or C 4 positions by the C(R )(R 3 )(amino acid) group to give compounds of formulae (IC) and (ID) respectively. Particularly preferred are those compounds of formula (I) where R 1 is attached at the C 4 position of the imidazole moiety and the C(R 2 )(R 3 )(amino acid) group is attached at the C 2 position so as to give the 2,4-disubstituted imidazole of formula (IC 1 ) or where R 1 is attached at the N 1 position of the imidazole moiety and the C(R 2 )(R 3 )(amino acid) group is attached at the C 4 position so as to give the 1 ,4-disubstituted imidazole of formula (ID 1 ).
• n is 0 or 1. More preferably n is 0.
• R 1 is hydrogen, Aryl, or a C1-6 alkyl or C 2 - ⁇ alkenyl group optionally substituted by one or more groups selected from C 3 . 7 cycloalkyl, Aryl, Aromatic heterocycle, Heterocycle, OR 10 , NR 10 R 11 , S(0) p R 1 °, OC(0)R 1 ⁇ C0 2 R 1 °, CONR 10 R 11 , SO 2 NR 10 R 11 , halo and NHS0 2 R 1 °. More preferably R 1 is hydrogen, Aryl, C 2-6 alkenyl or a Ci- 6 alkyl group optionally substituted by one or more groups selected from C 3 .
• R 1 is hydrogen, Aryl or a Ci- 6 alkyl group optionally substituted by a group selected from C 3 . 7 cycloalkyl, Aryl, Aromatic heterocycle, OR 10 , C0 2 R 1 ° and NHS0 2 R 10 .
• R 1 is hydrogen, Aryl or a Ci- ⁇ alkyl group optionally substituted by a group selected from cydohexyl and Aryl.
• R 1 is hydrogen or C ⁇ -3 alkyl. Most preferably R 1 is hydrogen.
• R 2 and R 3 are each independently selected from hydrogen and C ⁇ -6 alkyl. More preferably R 2 and R 3 are hydrogen.
• R 4 is hydrogen or C ⁇ - 6 alkyl. More preferably R 4 is hydrogen.
• R 6 , R 7 and R 9 are each independently selected from hydrogen and Ci-6 alkyl. More preferably R 6 , R 7 and R 9 are each independently selected from hydrogen and C 1 -3 alkyl. Yet more preferably R 6 , R 7 and R 9 are each independently selected from hydrogen and methyl. Most preferably R 6 , R 7 and R 9 are all hydrogen.
• R 5 and R 8 do not constitute a C 2-6 alkylene link then R 5 is preferably hydrogen or C-i- 6 alkyl, more preferably hydrogen or C ⁇ -3 alkyl, yet more preferably hydrogen or methyl, and most preferably methyl, and R 8 is preferably hydrogen or C ⁇ - 6 alkyl, more preferably hydrogen or C- ⁇ - 3 alkyl, yet more preferably hydrogen or methyl, and most preferably hydrogen.
• R 5 and R 8 constitute a C 2 - 6 alkylene link then the link is preferably a C2- 3 alkylene link and more preferably it is a C 2 alkylene link.
• R 10 and R 11 are each independently selected from hydrogen and C 1 . 3 aallkkyyll.. MMoonre preferably R 10 and R 11 are each independently selected from hydrogen and methyl
• Aryl includes optionally substituted phenyl, naphthyl, anthracenyl and phenanthrenyl.
• Aryl is phenyl or naphthyl optionally substituted by 1 -3 groups selected from R 12 , halo, OR 13 , NR 13 R 14 , NR 13 C0 2 R 12 , C0 2 R 13 , NR 13 S0 2 R 12 , CN, haloalkyl, O(haloalkyl), SR 13 , S(0)R 12 , S0 2 R 12 , OC(0)R 13 , S0 2 NR 13 R 14 , C(0)NR 13 R 14 , C 3 - 7 cycloakyl, O(C 3-7 cycloalkyl), R 15 and OR 15 .
• Aryl is phenyl optionally substituted by C ⁇ -6 alkyl, halo, 0(C ⁇ -6 alkyl), CF 3 , C 3 - 7 cycloakyl, 0(C 3-7 cycloalkyl), R 15 or OR 15 and R 15 is phenyl optionally substituted by C 1-6 alkyl, halo, 0(d. 6 alkyl) or CF 3 .
• Aryl is phenyl optionally substituted by Ci- ⁇ alkyl, CF 3 , cydohexyl, O(cyclohexyl), R 15 or OR 15 and R 15 is phenyl optionally substituted by C ⁇ -6 alkyl, Cl, F, 0(C ⁇ -6 alkyl) or CF 3 .
• Aryl is phenyl.
• Aromatic heterocycle is a 5 or 6 membered aromatic ring containing 1 or 2 heteroatoms each independently selected from O, S and N, including optionally substituted furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl and triazinyl, optionally substituted by 1-3 groups selected from OR 13 , NR 13 R 14 , C0 2 R 13 , NR 13 C0 2 R 12 , R 12 , halo, CN, haloalkyl, O(haloalkyl), SR 13 , S(O)R 12 , S0 2 R 12 , OC(O)R 13 , NR 13 S0 2 R 12 , S0 2 NR 13
• Aromatic heterocycle is a 5 or 6 membered aromatic ring containing from 1 to 3 heteroatoms, each independently selected from O, S and N, optionally substituted by 1-3 groups selected from OR 13 , NR 13 R 14 , C0 2 R 13 , NR 13 C0 2 R 12 , R 12 , halo, CN, haloalkyl, O(haloalkyl), SR 13 , S(0)R 12 , S0 2 R 12 , OC(0)R 13 , NR 13 S0 2 R 12 , S0 2 NR 13 R 14 , C(0)NR 13 R 14 .
• Aromatic heterocycle is an unsubstituted 5 or 6 membered aromatic ring containing 1 or 2 heteroatoms, each independently selected from O, S and N.
• Heterocycle is a 3 to 8 membered ring containing 1 or 2 heteroatoms, each independently selected from O, S and N, said ring being saturated or partially saturated, optionally substituted by 1 to 3 groups selected from OR 13 , NR 13 R 14 , C0 2 R 13 , NR 13 C0 2 R 12 , R 12 , halo, CN, haloalkyl, O(haloalkyl), SR 13 , S(O)R 12 , S0 2 R 12 , OC(0)R 13 , NR 13 S0 2 R 12 , SO 2 NR 13 R 14 , C(0)NR 13 R 14 .
• Heterocycle is a 5 or 6 membered ring containing 1 or 2 heteroatoms, each independently selected from O, S and N, said ring being saturated or partially saturated, optionally substituted by 1 to 3 groups selected from OR 13 , NR 13 R 14 , C0 2 R 13 , NR 13 C0 2 R 12 , R 12 , halo, CN, haloalkyl. O(haloalkyl), SR 13 , S(O)R 12 , S0 2 R 12 , OC(0)R 13 , NR 13 S0 2 R 12 , S0 2 NR 13 R 14 , C(0)NR 13 R 14 .
• Heterocycle is an unsubstituted 5 or 6 membered ring containing 1 or 2 heteroatoms, each independently selected from O, S and N, said ring being saturated or partially saturated, including oxiranyl, azetidinyl, tetrahydrofuranyl, thiolanyl, pyrrolidinyl, dioxolanyl, dihydropyranyl, tetrahydropyranyl, morpholinyl, piperidinyl and piperazinyl.
• Preferred compounds of the present invention are:
• (2S)-(-)-2-(2-aminoethoxy)-3-(1 -phenyl-1 -/-imidazol-4-yl)propanoic acid (Example 6); (2S)-2- ⁇ [(1 f?)-2-amino-1 -methylethyl]oxy ⁇ -3-[1 -(2-cyclohexylethyl)-1 H-imidazol-4-yl]- propanoic acid (Example 15); (2S)-2- ⁇ [(1 f7)-2-amino-1 -methylethyl]oxy ⁇ -3-(1 -phenyl-1 H-imidazol-4-yl)propanoic acid (Example 17);
• (2S)-2- ⁇ [(1 ?)-2-amino-1 -methylethyl]oxy ⁇ -3-[1 -(2-pyridinyl)-1 H-imidazol-4-yl]- propanoic acid (Example 52). Particularly preferred is (2 ⁇ -2- ⁇ [(1 f?)-2-amino-1-methylethyl]oxy ⁇ -3-(1 H-imidazol-4- yl)propanoic acid (Example 51).
• the compounds of formula (I) are inhibitors of TAFIa. Inhibition of TAFIa can be demonstrated using an assay based on the method of Boffa et al. (J. Biol. Chem. 1998, 273, 2127) as further described below.
• the activity of the compounds is characterized by a calculated Kj value.
• the compounds of the present invention have a Ki value of 10 ⁇ M or less. Better compounds have a Kj value of 1 ⁇ M or less, or even 100nM or less. The most potent compounds have a Kj value of 25nM or less.
• the compounds of formula (I) are selective for TAFIa over other carboxypeptidases, and particularly carboxypeptidase N (CPN). Unwanted inhibition of CPN is considered to be the most likely cause of undesirable side effects in clinical use. Selectivity can be expressed as the ratio of the Ki for TAFIa to the Kj for CPN.
• the compounds of the present invention have a selectivity ratio of at least 5. Better compounds have a selectivity ratio of at least 10. The most selective compounds have a selectivity ratio of at least 50.
• the compounds of formula (I) may be prepared according to the general methods which are described below and in the Examples and Preparations section. These methods provide a further aspect of the present invention. Nevertheless, the skilled man will appreciate that the compounds of the invention could be made by methods other than those herein described, by adaptation of the methods herein described and/or adaptation of a plethora of methods known in the art. It is to be understood that the synthetic transformation methods specifically mentioned herein may be carried out in various different sequences in order that the desired substances can be efficiently assembled. The skilled chemist will exercise his judgement and skill as to the most efficient sequence of reactions for the synthesis of a given target substance.
• P 1 is preferably a lower alkyl group such as methyl or ethyl, in which case suitable conditions for this step include treatment with NaOH in dioxan for 1 -3 days.
• Compounds of formula (II) may be prepared from the corresponding protected amines of formula (III) (wherein P 2 is a te/f-butyloxycarbonyl, benzyloxycarbonyl or fluorenylmethyloxycarbonyl group, or any other amine protecting group). Where R 9 is H then the preparation involves only a deprotection step. Where R 9 is other than H then a further step is necessary to introduce R 9 , such as a reductive amination reaction.
• Compounds of formula (III) may be prepared from imidazoleacetic acid derivatives of formula (V), wherein X is a leaving group such as a chlorine, bromine or iodine atom, or a methanesulphonate or trifluoromethanesulphonate group, by reaction with a alcohol of formula (VI).
• X is a leaving group such as a chlorine, bromine or iodine atom, or a methanesulphonate or trifluoromethanesulphonate group
• Compounds of formula (III) may alternatively be prepared from ⁇ -hydroxyimidazole- acetic acid derivatives of formula (VII) by reaction with a compound of formula (IX) wherein Y is a leaving group such as a chlorine, bromine or iodine atom, or a methanesulphonate or trifluoromethanesulphonate group.
• Y is a leaving group such as a chlorine, bromine or iodine atom, or a methanesulphonate or trifluoromethanesulphonate group.
• Compounds of formula (X) may be prepared from compounds of formula (XI) by dehydration.
• the transformation may be accomplished using, for example, methanesulfonyl chloride and a tertiary amine.
• Compounds of formula (XI) may be prepared by an aldol-type reaction between alkoxy-esters of formula (XII) and aldehydes or ketones of formula (XIII) in the presence of a strong base, such as lithium diisopropylamide.
• Compounds of formula (XVI) may be prepared by reacting an aldehyde or ketone of formula (Xlll) with a lactam of formula (XVII) in the presence of a strong base, such as lithium diisopropylamide.
• Compounds of formula (XVII) may be prepared from aminoalcohols of formula (XVIII) by reaction with chloroacetyl chloride.
• Compounds of formula (XVIII) are generally known, or may be prepared by adaptation of generally known methods.
• R 1 When R 1 is H it may be necessary or convenient to protect the imidazole as its trityl derivative. Accordingly, when R 1 is H, compounds of formula (XIX), (XX) or (XXI) may be elaborated by the foregoing methods to provide compounds of formula (XXII) which, upon deprotection, give compounds of formula (III).
• R 1 is an alkyl, alkenyl or alkynyl group it may be introduced in an alkylation reaction.
• Suitable conditions for this step include treatment with 1.1 eq of cesium carbonate and 1.1 eq of an alkylating agent in N ( N-dimethylformamide, or with sodium hydride and 1.1 eq of an alkylating agent in THF.
• Suitable alkylating reagents include R 1 -CI, R 1 -Br, R 1 -l, R 1 -OS0 2 CH 3 and R 1 -OS0 2 CF 3 .
• R 1 is Aryl or Aromatic heterocycle it may be introduced in an arylation reaction.
• Suitable conditions for this step include treatment with 2eq of Aryl-B(OH) 2 or Aromatic heterocycle-B(OH) 2 in the presence of 1.5 eq of copper acetate, 2eq of pyridine, air and 4A molecular sieves.
• the compounds of formula (I) are useful as therapeutic agents.
• the compounds will generally be formulated so as to be amenable to administration to the subject by the chosen route.
• the present invention provides for a pharmaceutical composition comprising a compound of formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt, solvate or prodrug thereof and a pharmaceutically acceptable excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
• the compounds of formula (I) can be administered orally, buccally or sublingually in the form of tablets, capsules, ovules, elixirs, solutions or suspensions.
• These formulations may contain flavouring or colouring agents, and may be adapted for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications.
• Tablets may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glycollate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropyl- cellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.
• Solid compositions of a similar type may also be employed as fillers in gelatin capsules.
• Preferred excipients in this regard include lactose, starch, cellulose and derivatives thereof, milk sugar and high molecular weight polyethylene glycols.
• the compounds of formula (I) may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents, and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.
• the compounds of formula (I) may also be administered in the form of a solution- or suspension-filled soft or hard gelatin capsule.
• Such capsules are generally made of gelatin, glycerin, water and sorbitol.
• Hard capsules are distinguished from soft capsules by containing less water and thus having a correspondingly stronger shell. Additional excipients suitable for use in such capsules include propylene glycol, ethanol, water, glycerol and edible oils.
• the compounds of formula (I) can also be administered parenterally, for example, intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracranially, intramuscularly or subcutaneously.
• parenterally for example, intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracranially, intramuscularly or subcutaneously.
• Such administration may be as a single bolus injection or as a short- or long-duration infusion.
• the compounds are preferably formulated as a sterile solution in water or another suitable solvent or mixture of solvents.
• the solution may contain other substances such as: salts, particularly sodium chloride, and sugars, particularly glucose or mannitol, to make the solution isotonic with blood; buffering agents such as acetic, citric and phosphoric acids and their sodium salts, such that the pH of the solution is preferably between 3 and 9; and preservatives.
• salts particularly sodium chloride
• sugars particularly glucose or mannitol
• buffering agents such as acetic, citric and phosphoric acids and their sodium salts, such that the pH of the solution is preferably between 3 and 9
• preservatives such as acetic, citric and phosphoric acids and their sodium salts
• the compounds of formula (I) can also be administered intranasally or by inhalation and are conveniently delivered in the form of a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray, atomiser or nebuliser, with or without the use of a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, a hydrofluoroalkane such as 1 ,1 ,1 ,2-tetrafluoroethane (HFA 134ATM) or 1 ,1 ,1 , 2,3,3,3-heptafluoropropane (HFA 227EATM), carbon dioxide or other suitable gas.
• a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, a hydrofluoroalkane such as 1 ,1 ,1 ,2-
• the dosage unit may be determined by providing a valve to deliver a metered amount.
• the pressurised container, pump, spray, atomiser or nebuliser may contain a solution or suspension of the active compound, e.g. using a mixture of ethanol and the propellant as the solvent, which may additionally contain a lubricant, e.g. sorbitan trioleate.
• Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated to contain a powder mix of a compound of the formula (I) and a suitable powder base such as lactose or starch.
• the compounds of formula (I) can be administered by the vaginal or rectal routes in the form of a suppository or pessary, or The compounds of formula (I) may also be administered dermally or transdermally, for example, by the use of a skin patch.
• the compounds of formula (I) can be applied topically in the form of a gel, hydrogel, lotion, solution, cream, ointment or dusting powder.
• Suitable ointments may contain the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water.
• Suitable lotions or creams may contain the active compound suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
• the compounds of formula (I) may be administered by the ocular route.
• the compounds can be formulated as micronised suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzylalkonium chloride.
• they may be formulated in an ointment such as petrolatum.
• the compounds of formula (I) may also be used in combination with a cydodextrin.
• Cyclodextrins are known to form inclusion and non-inclusion complexes with drug molecules. Formation of a drug-cyclodextrin complex may modify the solubility, dissolution rate, bioavailability and/or stability property of a drug molecule. Drug- cyclodextrin complexes are generally useful for most dosage forms and administration routes.
• the cydodextrin may be used as an auxiliary additive, e.g. as a carrier, diluent or solubiliser.
• Alpha-, beta- and gamma-cyclodextrins are most commonly used and suitable examples are described in W091/11172, WO94/02518 and W098/55148.
• the compounds of formula (I) are inhibitors of TAFIa they are useful as therapeutic agents in pathologies in which inhibition of TAFIa is beneficial.
• the present invention provides for a compound of formula (I) or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt or prodrug thereof for use as a medicament.
• the present invention provides for the use of a compound of formula (I) or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt or prodrug thereof in the preparation of a medicament for the treatment or prevention of a condition selected from thrombotic conditions, atherosclerosis, adhesions, dermal scarring, cancer, fibrotic conditions, inflammatory diseases and those conditions which benefit from maintaining or enhancing bradykinin levels in the body.
• TAFIa inhibitors for the treatment of thrombotic conditions derives from their potential to promote fibrinolysis while not interfering with coagulation. In most clinically relevant situations thrombus formation is sub-acute, i.e. the thrombus forms slowly.
• TAFIa inhibitors accelerate the dissolution of the developing thrombus without interfering with the clotting response.
• one preferred embodiment of the present invention provides for the use of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or prodrug thereof in the preparation of a medicament for the treatment of a thrombotic condition selected from myocardial infarction, deep vein thrombosis, stroke, young stroke, cerebral infarction, cerebral thrombosis, cerebral embolism, peripheral vascular disease, angina and other forms of acute coronary syndromes, disseminated intravascular coagulation, sepsis, pulmonary embolism, embolic events secondary to cardiac arrhythmias and the prevention of cardiovascular events following surgical revascularisation or intervention, or for improving the outcome of organ transplantation by reducing blood clotting and so preserving organ function.
• a thrombotic condition selected from myocardial infarction, deep vein thrombosis, stroke, young stroke, cerebral infarction, cerebral thrombosis, cerebral embolism, peripheral vascular disease, angina and other forms of acute coronary syndromes, disseminated
• Cardiovascular events following intervention surgery include conditions such as restenosis or reocdusion following interventions such as percutaneous transluminal coronary angioplasty, grafting, stent in-placement, coronary bypass surgery or any other forms of surgical revascularisation or intervention.
• Disseminated intravascular coagulation includes all conditions resulting from intravascular activation of the coagulation process. This might occur acutely through the release of procoagulant substances (eg. obstetric emergencies, snakebite, crush injury malignancy), by abnormal contact of the blood (eg. infections, burns, extracorporeal circulation, grafts) or though generation of procoagulants in the blood (transfusion reactions, leukemia); or chronically, (eg.
• Deep vein thrombosis also encompasses what is known as 'economy class syndrome', where clots form in subjects forced to endure cramped conditions for a period of time, such as those sitting in the economy class seats of an aeroplane.
• Non-ocdusive thrombi not only restrict blood flow leading to myocardial ischemia and angina pectoris but also, due to incomplete endogenous lysis, may be incorporated into the arterial wall as solidified plaque material enhancing the atherosclerotic process.
• Long-term administration of a TAFIa inhibitor promotes the lysis of developing thrombi and therefore provides a safe and efficacious treatment which alleviates the symptoms of angina pectoris while impairing the progression of the underlying disease.
• Conventional treatment of myocardial ischaemia in clinically stable coronary artery disease is predominately designed to reduce cardiac workload and enhance blood flow.
• Another preferred embodiment of the present invention provides for the use of compounds of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof in the preparation of a medicament for the treatment or prevention of atherosclerosis, including atherosclerosis as a consequence of peripheral vascular disease, insulin resistance and Syndrome X, and further including myocardial ischaemia and angina pectoris resulting from atherosclerosis.
• Atherosclerosis is taken to include both primary and secondary coronary artery disease, in which atherosclerosis restricts the blood supply to the heart.
• Primary prevention of coronary artery disease means preventing the onset of ischemic complications such as myocardial infarction in patients with no history of coronary artery disease but who have one or more risk factors.
• Secondary prevention of coronary artery disease means preventing ischemic complications in patients with established coronary artery disease, such as patients who have had a previous myocardial infarction.
• Syndrome X is a term often used to group together a number of interrelated diseases. The first stage of syndrome X consists of insulin resistance, abnormal cholesterol and triglyceride levels, obesity and hypertension. Any one of these conditions may be used to diagnose the start of Syndrome X.
• the disease may then progress with one condition leading to the development of another in the group.
• insulin resistance is associated with high lipid levels, hypertension and obesity.
• the disease then cascades, with the development of each additional condition increasing the risk of developing more serious diseases. This can progress to the development of diabetes, kidney disease and heart disease. These diseases may lead to stroke, myocardial infarction and organ failure. Atherosclerosis is common in patients with Syndrome X.
• TAFIa inhibitors are also effective in preventing the formation of adhesions in the body. Most surgical procedures and physical traumas result in bleeding into the cavities between tissues. The blood which collects at these sites then clots forming fibrin-rich thrombi. These thrombi bridge the gaps between adjacent tissues and act as foci for the accumulation of inflammatory cells and fibroblasts. Invading fibroblasts lay down a collagen-rich extracellular matrix which strengthens the adhesion of the tissues producing a firm bond which may then restrict movement. Adhesions have been characterised according to their location and may result following any surgery, e.g. abdominal, orthopaedic, neurological, cardiovascular and ocular surgery.
• Treatment with a TAFIa inhibitor around and/or after surgical intervention may enhance fibrinolysis of the fibrin-rich thrombi and hence inhibit thrombus formation, accretion and stabilization, thereby inhibiting adhesion formation.
• a TAFIa inhibitor given either locally as a topical application or systemically may be seen to be of benefit in a range of surgical procedures.
• administration of a TAFIa inhibitor may be used to treat adhesions resulting from other forms of non-surgical physical trauma where this has caused internal bleeding. Examples of such trauma might include sporting injuries or anything else resulting in a tear, cut, bruise or induration of the body.
• Another preferred embodiment of the present invention provides for the use of compounds of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof in the preparation of a medicament for the treatment or prevention of a medicament for the treatment or prevention of adhesions or dermal scarring.
• TAFIa inhibitors are also effective in inhibiting tumour maturation, progression and metastasis. Without being bound by any theory, it is believed that the hemostatic system is involved at several levels of cancer pathology, including neovascularisation, shedding of cells from the primary tumour, invasion of the blood supply, adherence to the vessel wall and growth at the metastatic site. It is thought that the efficacy of TAFIa inhibitors stems from an ability to reduce fibrin deposition around solid tumours and thereby inhibit the above processes. Accordingly, another preferred embodiment of the present invention provides for the use of compounds of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof in the preparation of a medicament for the treatment or prevention of cancer.
• TAFIa inhibitors are efficacious in treatment of any condition in which fibrosis is a contributing factor.
• Suitable fibrotic conditions include cystic fibrosis, pulmonary fibrotic diseases such as chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), fibromuscular dysplasia and fibrotic lung disease, and fibrin deposition in the eye during opthalmic surgery.
• another preferred embodiment of the present invention provides for the use of compounds of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof in the preparation of a medicament for the treatment or prevention of fibrotic disease, and in particular for the treatment or prevention of a fibrotic condition selected from cystic fibrosis, pulmonary fibrotic diseases, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), fibromuscular dysplasia, fibrotic lung disease and fibrin deposition in the eye during opthalmic surgery.
• a fibrotic condition selected from cystic fibrosis, pulmonary fibrotic diseases, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), fibromuscular dysplasia, fibrotic lung disease and fibrin deposition in the eye during opthalmic surgery.
• TAFIa inhibitors are efficacious in the treatment of inflammation, inflammatory diseases such as asthma, arthritis, endometriosis, inflammatory bowel diseases, psoriasis and atopic dermatitis and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.
• inflammatory diseases such as asthma, arthritis, endometriosis, inflammatory bowel diseases, psoriasis and atopic dermatitis and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.
• another preferred embodiment of the present invention provides for the use of compounds of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof in the preparation of a medicament for the treatment or prevention of inflammation, inflammatory diseases such as asthma, arthritis, endometriosis, inflammatory bowel diseases, psoriasis and atopic dermatitis and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.
• TAFIa binds to and breaks down bradykinin (Tan et al., Biochemistry 1995, 34, 5811).
• bradykinin There are many conditions which are known to benefit from maintaining or enhancing levels of bradykinin such as hypertension, angina, heart failure, pulmonary hypertension, renal failure and organ failure.
• another preferred embodiment of the present invention provides for the use of compounds of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof in the preparation of a medicament for the treatment or prevention of conditions which benefit from maintaining or enhancing levels of bradykinin.
• the present invention provides a method of treating or preventing thrombotic conditions, atherosclerosis, adhesions, dermal scarring, cancer, fibrotic conditions, inflammatory diseases and those conditions which benefit from maintaining or enhancing bradykinin levels in the body which comprises administering a therapeutically effective amount of a compound of formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt, solvate or prodrug thereof to a patient in need of such treatment.
• One preferred embodiment of the present invention provides for a method of treating or preventing thrombosis, particularly myocardial infarction, deep vein thrombosis, stroke, young stroke, cerebral infarction, cerebral thrombosis, cerebral embolism, peripheral vascular disease, angina and other forms of acute coronary syndromes, disseminated intravascular coagulation, sepsis, pulmonary embolism, embolic events secondary to cardiac arrhythmias and preventing cardiovascular events following intervention surgery which comprises administering a therapeutically effective amount of a compound of formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt, solvate or prodrug thereof to a patient in need of such treatment.
• thrombosis particularly myocardial infarction, deep vein thrombosis, stroke, young stroke, cerebral infarction, cerebral thrombosis, cerebral embolism, peripheral vascular disease, angina and other forms of acute coronary syndromes, disseminated intravascular coagulation, sepsis
• Subjects with thrombotic conditions who are suitable for treatment by the present invention include those having conditions associated with hypercoagulability, such as factor V mutation, antithrombin III deficiency, heparin cof actor II deficiency, protein C deficiency, protein S deficiency and polycythemia vera, and those exhibiting homocystinaemia or homocystinuria.
• Another preferred embodiment of the present invention provides for a method of treating or preventing atherosclerosis which comprises administering a therapeutically effective amount of a compound of formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt, solvate or prodrug thereof to a patient in need of such treatment.
• Another preferred embodiment of the present invention provides for a method of treating or preventing adhesions or dermal scarring which comprises administering a therapeutically effective amount of a compound of formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt, solvate or prodrug thereof to a patient in need of such treatment.
• Another preferred embodiment of the present invention provides for a method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt, solvate or prodrug thereof to a patient in need of such treatment.
• Another preferred embodiment of the present invention provides for a method of treating or preventing a fibrotic condition such as cystic fibrosis, pulmonary fibrotic diseases, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), fibromuscular dysplasia, fibrotic lung disease and fibrin deposition in the eye during ophthalmic surgery which comprises administering a therapeutically effective amount of a compound of formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt, solvate or prodrug thereof to a patient in need of such treatment.
• a fibrotic condition such as cystic fibrosis, pulmonary fibrotic diseases, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), fibromuscular dysplasia, fibrotic lung disease and fibrin deposition in the eye during ophthalmic surgery which comprises administering a therapeutically effective amount of a compound of formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt,
• Another preferred embodiment of the present invention provides for a method of treating or preventing an inflammatory disease such as asthma, arthritis, endometriosis, inflammatory bowel diseases, psoriasis or atopic dermatitis or a neurodegenerative disease such as Alzheimer's disease or Parkinson's disease which comprises administering a therapeutically effective amount of a compound of formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt, solvate or prodrug thereof to a patient in need of such treatment.
• an inflammatory disease such as asthma, arthritis, endometriosis, inflammatory bowel diseases, psoriasis or atopic dermatitis or a neurodegenerative disease such as Alzheimer's disease or Parkinson's disease
• Another preferred embodiment of the present invention provides for a method of treating or preventing conditions which benefit from maintaining or enhancing levels of bradykinin which comprises administering a therapeutically effective amount of a compound of formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt, solvate or prodrug thereof to a patient in need of such treatment.
• the amount of compound administered and the frequency of administration will be determined by the attending physician taking into account the characteristics of the patient, such as age, weight and state of health, and the degree of inhibition of TAFIa desired.
• the total daily dose for a typical 70kg adult will generally be between 1mg and 5g, preferably between 10mg and 1g, more preferably between 50mg and 750mg. The total dose may be given as a single or divided dose.
• the compounds of the present invention may be used alone or in combination with other therapeutic agents.
• the administration of the two agents may be simultaneous or sequential.
• Simultaneous administration includes the administration of a single dosage form that comprises both agents and the administration of the two agents in separate dosage forms at substantially the same time.
• Sequential administration includes the administration of the two agents according to different schedules provided that there is an overlap in the periods during which the treatment is provided.
• Suitable agents with which the compounds of formula (I) can be co-administered include antithrombotics, including antiplatelet agents, anticoagulants and profibrinolytics.
• Suitable antithrombotics include: aspirin, PlavixTM, ticlopidine, warfarin (CoumadinTM), unfractionated heparin, hirudin (LepirudinTM), streptokinase, urokinase, recombinant tissue plasminogen activator (tPA), dipyridamole, ReoproTM, AggrastatTM, and IntegrilinTM.
• the compounds of formula (I) can also be administered together with antihypertensive agents and with agents to treat dyslipidaemia such as statins eg LipitorTM.
• Further suitable drug classes for co-administration include Factor X inhibitors and antiarrhythmics such as amiodarone or digoxin.
• the present invention provides for the use of a compound of formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt, solvate or prodrug thereof in combination with an antithrombotic agent for the preparation of a medicament for the treatment of thrombosis.
• an antithrombotic agent for the preparation of a medicament for the treatment of thrombosis.
• the antithrombotic is an profibrinolytic.
• the antithrombotic is recombinant tissue plasminogen activator (tPA).
• the present invention provides for a method of treating or preventing thrombosis, which comprises administering a therapeutically effective amount of a compound of formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt, solvate or prodrug thereof in combination with an antithrombotic to a patient in need of such treatment.
• the antithrombotic is a profibrinolytic.
• the antithrombotic is recombinant tissue plasminogen activator (tPA).
• the present invention provides for a kit comprising: a) a composition comprising a compound of formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt, solvate or prodrug thereof as disclosed herein and a pharmaceutically acceptable diluent or carrier; b) a composition comprising an antithrombotic and a pharmaceutically acceptable diluent or carrier; and c) a container
• the components of this kit may be administered separately, simultaneously or sequentially.
• the present invention also provides for the use a compound of formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt, solvate or prodrug thereof as a coating on intravascular devices such as indwelling catheters for dialysis, replacement heart valves or arterial stents; and as a coating on extra- corporeal blood circulation devices such as heart, lung and kidney dialysis machines, to prevent thrombosis, particularly myocardial infarction, deep vein thrombosis, stroke, young stroke, cerebral infarction, cerebral thrombosis, cerebral embolism, peripheral vascular disease, angina and other forms of acute coronary syndromes, disseminated intravascular coagulation, sepsis, pulmonary embolism, embolic events secondary to cardiac arrhythmias and the prevention of cardiovascular events such as restenosis following intervention surgery such as percutaneous transluminal coronary angioplasty, grafting, stent in-placement, coronary bypass surgery or any other forms of surgical revascularisation or intervention
• the invention provides for intravascular devices, of which the intravascular portion is coated with a compound of formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt, solvate or prodrug thereof; and extra corporeal blood circulation devices such as heart, lung and kidney dialysis machines, where the portion coming into contact with the subjects blood is coated with a compound of formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt, solvate or prodrug thereof.
• the compounds of the present invention are TAFIa inhibitors, whose utility is based upon preventing the reaction between a developing thrombus and TAFIa. It has been found that the compounds of the present invention are also capable of binding to the unactivated TAFI molecule, at the site implicated in the reaction between TAFIa and the developing clot.
• TAFIa inhibitors as described above in terms of scope and utility, includes such TAFIa inhibitors which bind to TAFI.
• Proton NMR spectra were measured on a Varian Inova 300, Varian Inova 400, or Varian Mercury 400 spectrometer in the solvents specified. In the NMR spectra, only non- exchangeable protons which appeared distinct from the solvent peaks are reported. Low resolution mass spectra were recorded on either a Fisons Trio 1000, using thermospray positive ionisation, or a Finnigan Navigator, using electrospray positive or negative ionisation. High resolution mass spectra were recorded on a Bruker Apex II FT-MS using electrospray positive ionisation. Combustion analyses were conducted by Schwarz Analytical UK. Ltd., Uxbridge, Middlesex.
• Optical rotations were determined at 25°C using a Perkin Elmer 341 polarimeter using the solvents and concentrations specified.
• Example compounds designated as (+) or (-) optical isomers are assigned based on the sign of optical rotation when determined in a suitable solvent.
• HyfloTM Hyflo supercel® from Aldrich Chemical Company liq liquid
• lmidazole-4-carboxaldehyde (30g, 0.31 mol) was added portionwise to a solution of sodium hydride (13.9g, 60% dispersion in mineral oil, 0.348mol) in tetrahydrofuran (450ml), and the solution was stirred for 45 minutes.
• n-Propyl bromide (31.2ml, 0.344mol) was then added portionwise, followed by 18-crown-6 (150mg), and the mixture was heated under reflux for 18 hours.
• Aqueous ammonium chloride solution was added to the cooled solution, and the mixture was extracted with ethyl acetate (2x) and dichloromethane (2x). The combined organic extracts were dried (MgS0 ), filtered, and concentrated under reduced pressure.
• lmidazole-4-carboxaldehyde (4.8g, 50mmol) was added portionwise to a suspension of sodium hydride (2.20g, 60% dispersion in mineral oil, 55mmol) in tetrahydrofuran (150ml), and the mixture was then stirred at room temperature for 1 hour.
• 2- Cydohexylethyl bromide (8.6ml, 55mmol) was added, and the mixture was heated under reflux for 18 hours. The cooled mixture was evaporated under reduced pressure and the residue was partitioned between water (500ml) and dichloromethane (500ml). The layers were separated, and the organic phase was dried (MgS0 ) and evaporated under reduced pressure.
• lmidazole-4-carboxaldehyde (673g, 70mmol) was added portionwise to a suspension of sodium hydride (1.68g, 60% dispersion in mineral oil, 70mmol) in tetrahydrofuran (280ml), and the mixture was then stirred at room temperature for 30 minutes.
• (2-Bromoethyl)benzene (9.56ml, 70mmol) was added, and the mixture was stirred at room temperature for 72 hours.
• the mixture was evaporated under reduced pressure and the residue was partitioned between water (300ml) and dichloromethane (500ml), and the layers were separated.
• the organic phase was dried (MgS0 4 ) and evaporated under reduced pressure.
• Acetic acid (ca. 150ml) was added to a solution of p-anisaldehyde (58.2g, 0.42mol) and ethanolamine (152ml, 2.52mol) in methanol (1 L), to achieve a pH of 6.
• Sodium triacetoxyborohydride (100g, 0.47mol) was added portionwise, and once addition was complete, the mixture was stirred at room temperature for 72 hours. The mixture was concentrated under reduced pressure, basified using 1 N sodium hydroxide solution and extracted with dichloromethane (10x300ml).
• the reaction mixture was concentrated under reduced pressure and the residue was partitioned between dichloromethane (150ml) and sodium hydroxide solution (150ml, 0.5N). The layers were separated and the aqueous phase was saturated with sodium chloride, then extracted with further dichloromethane (3x30ml). The combined organic solutions were dried (MgS0 4 ) and evaporated under reduced pressure. The residue was purified by chromatography on silica gel (gradient elution 98:2:0.2 to 97:3:0.3 dichloromethane:methanol:0.88 NH 3 ) to afford an orange oil (4.9g).
• N,N-Dimethylethanolamine (5.02ml, 50mmol) was added dropwise over 5 minutes to an ice-cooled suspension of sodium hydride (2.2g, 60% dispersion in mineral oil, ⁇ mmol) in tetrahydrofuran (100ml), and the solution was stirred for 30 minutes.
• tert-Butyl bromoacetate (7.38ml, ⁇ Ommol) was added dropwise over ⁇ minutes, then the mixture was allowed to warm to room temperature and stirred for a further 18 hours.
• Sodium hydride (704mg, 60% in mineral oil, 17.6mmol) was added to an ice-cooled solution of tert-butyl (3r7)-3-hydroxypyrrolidine-1 -carboxylate (J. Med. Chem. 1998, 41(25), 4983) ( ⁇ g, 267mmol) in tetrahydrofuran (100ml), and the mixture was allowed to warm to room temperature and stirred for 20 minutes.
• tert-Butyl bromoacetate ( ⁇ .2g, 267mmol) was added and the mixture was heated under reflux for 18 hours, then cooled and concentrated under reduced pressure. The residue was partitioned between ethyl acetate and water and the phases separated.
• Trimethylsilyl chloride (1.3ml, 10.2mmol), copper (I) chloride (30mg, 0.3mmol) and cyclohexylmagnesium chloride (4.6ml, 2N in diethyl ether, 9.2mmol) were added slowly to an ice-cooled solution of ethyl 3,3-dimethylacrylate (1g, ⁇ . ⁇ mmol) in 0 tetrahydrofuran (10ml). The solution was stirred for 10 minutes, then allowed to warm to room temperature and stirred for an hour. Saturated aqueous ammonium chloride solution (10ml) was added and the mixture was partitioned between water (10ml) and diethyl ether (20ml).
• Lithium borohydride (1.23g, ⁇ 6.6mmol) was added to a solution of the ester of Preparation 19 (4g, 18.9mmol) in tetrahydrofuran (30ml), and the mixture was stirred 6 at 60°C for 18 hours.
• Aqueous ammonium chloride solution (15ml) was added carefully to the cooled solution, and the mixture was extracted with ethyl acetate (3x30ml). The combined organic extracts were washed with brine, dried (MgS0 4 ) and evaporated under reduced pressure.
• the crude product was purified by column chromatography on silica gel using ethyl acetate:pentane (20:80) as eluant to afford the title compound, 1g.
• Triphenylphosphine (1.8g, 7.1 mmol) was added portionwise to an ice-cooled solution of the alcohol of Preparation 20 (1g, 5.9mmol) and carbon tetrabromide (2.9g, 8.8mmol) in dichloromethane (15ml), and once addition was complete, the mixture was stirred at room temperature for 72 hours. The solution was concentrated under reduced pressure and the residue was suspended in a mixture of pentane:ethyl acetate ( ⁇ :1 , by volume). The resulting precipitate was filtered off through a pad of silica gel and washed with pentane:ethyl acetate ( ⁇ :1 , by volume, 300ml).
• Lithium diisopropylamide (17.4ml, 2M in heptane/tetrahydrofuran/ethylbenzene, 34.8mmol) was added over 10 minutes to a cooled (-78°C) solution of the compound of Preparation 10 (3.42g, 29mmol) in tetrahydrofuran (100ml), and the resulting solution was stirred for 20 minutes.
• the aldehyde of Preparation 1 (4.81 g, 34.8mmol) was added and the mixture was allowed to warm slowly to room temperature, then stirred for 18 hours.
• Aqueous ammonium chloride solution (20ml) was added, and the mixture was evaporated under reduced pressure.
• Lithium diisopropylamide (4.3ml, 2M in heptane/tetrahydrofuran/ethylbenzene, 8.6mmol) was added dropwise over 5 minutes to a solution of the amine of Preparation 17 (1.46g, 7.2mmol) in tetrahydrofuran (20ml) and the solution was stirred at -78°C for 20 minutes.
• the aldehyde of Preparation 1 (1.18g, 8.6mmol) was added and the mixture was stirred for 3 hours then allowed to warm to -20°C. Water was added, and the mixture pre-adsorbed onto silica gel.
• Triethylamine (9.19ml, 65.9mmol) was added to a solution of the alcohol of Preparation 23 (15.8g, 44.0mmol) in dichloromethane (300ml). The solution was cooled in ice, methanesulphonyl chloride (5.1ml, 65.9mmol) was added, and the solution was stirred for 2 hours at room temperature. Additional triethylamine (3.06ml, 22mmol) was added, and the mixture was stirred at 40°C for 18 hours then cooled. The mixture was diluted with dichloromethane (1000ml) and washed with sodium bicarbonate solution (200ml).
• Methanesulphonyl chloride (911 ⁇ l, 1178mmol) was added dropwise to an ice-cooled solution of the alcohol of Preparation 30 (4.5g, 7.85mmol) in dichloromethane (40ml) and triethylamine (1.64ml, 1178mmol), and the solution was stirred at room temperature for 1 hour. Additional triethylamine (546 ⁇ l, 3.93mmol) was added, and the mixture was stirred at 40°C for 18 hours. The cooled mixture was partitioned between dichloromethane (50ml) and water (50ml) and the layers were separated. The organic phase was dried (MgS0 4 ) and concentrated under reduced pressure.
• Triethylamine (178ml, 12.8mmol) was added to a solution of the alcohol of
• Triethylamine (0.98ml, 7.03mmol) was added to a solution of the alcohol of Preparation 27 (1.41 g, 3.35mmol) in dichloromethane (15ml). The solution was cooled in ice, methanesulphonyl chloride (311 ⁇ l, 4.02mmol) was added, and the mixture was warmed to 40°C and stirred for 18 hours, then concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using an elution gradient of pentane:ethyl acetate: methanol (75:25:0 to 0:100:0 to 0:95:5) to afford the title compound as an orange oil, 449mg.
• Methanesulphonyl chloride (340 ⁇ l, 4.4mmol) was added dropwise to an ice-cooled solution of the alcohol of Preparation 33 (1.36g, 4.0mmol) and triethylamine (616 ⁇ l, 4.4mmol) in dichloromethane (20ml). The solution was stirred at room temperature for 1 hour, additional triethylamine (616 ⁇ l, 4.4mmol) was added, and the solution was stirred at room temperature for 18 hours. TLC analysis showed starting material remaining, so the solution was heated to reflux and stirred for a further 3 hours.
• Triethylamine (3.32ml, 23.8mmol) was added to a solution of the alcohol of
• Preparation 24 (5.47g, 21.6mmol) in dichloromethane (80ml), and the solution was cooled in ice.
• a solution of methanesulphonyl chloride (1.84ml, 23.8mmol) in dichloromethane (3ml) was added over 5 minutes, and the solution was stirred at room temperature for 1 hour.
• the mixture was evaporated under reduced pressure, the residue was dissolved in N,N-dimethylformamide (15ml), triethylamine (3.32ml, 23.8mmol) was added, and the solution was heated at reflux and stirred for 20 minutes.
• the crude product was purified twice by column chromatography on silica gel using first an elution gradient of dichloromethane:methanol:0.88 ammonia (100:0:0 to 95:5:0.5), then using an elution gradient of ethyl acetate:diethylamine (100:0 to 95:5), to afford the title compound, as a colourless gum, 191 mg.
• the product was further purified by column chromatography using a Biotage ® silica gel column, and an elution gradient of toluene:diethylamine (100:0 to 88:12) to afford the title compound as a pale yellow gum, 120mg.
• Ammonium cerium (IV) nitrate (4.55g, 8.30mmol) was added to a solution of the compound of Preparation 47 (1.43g, 4.15mmol) in acetonitrile (9ml) and water (9ml) and the mixture was stirred at room temperature for 18 hours then concentrated under reduced pressure and the residue was dissolved in methanol.
• This solution was purified by column chromatography on silica gel using an elution gradient of dichloromethane:methanol:0.88 ammonia (95:5:0.5 to 90:10:1) to afford an orange oil.
• Ammonium cerium (IV) nitrate (57g, 10.4mmol) was added to a solution of the compound of Preparation 48 (1.87g, 5.2mmol) in acetonitrile (50ml) and water (50ml), and the mixture was stirred at room temperature for 18 hours.
• the solvents were evaporated under reduced pressure and the residue was purified using a Dowex ® 50WX8-200 ion-exchange column and 5% 0.88 ammonia as eluant. This product was further purified by column chromatography on silica gel using an elution gradient of dichloromethane:methanol:0.88 ammonia (100:0:0 to 90:10:1) to afford the title compound, 300mg.
• Ammonium cerium (IV) nitrate (1.1g, 2.0mmol) was added to a solution of the compound of Preparation 49 (411 mg, 1.Ommol) in acetonitrile (5ml) and water (5ml), and the mixture was stirred at room temperature for 18 hours then concentrated under reduced pressure. The residue was pre-adsorbed onto silica gel and purified by column chromatography on silica gel using an elution gradient of ethyl acetate:dichloromethane:methanol:0.88 ammonia (100:0:0:0 to 75:0:25:0 to 0:90:10:1).
• Ammonium cerium (IV) nitrate (387mg, 0758mmol) was added to a solution of the compound of Preparation 61 (120mg, 0.283mmol) in acetonitrile (8ml) and water (5ml) and the mixture was stirred at 40°C for 18 hours then concentrated under reduced pressure. The residue was pre-adsorbed onto silica gel and purified by column chromatography on silica gel using an elution gradient of dichloromethane:methanol:0.88 ammonia (98:2:0.2 to 95:5:0.5) to afford the title compound as a colourless oil, 66mg.
• Ammonium cerium (IV) nitrate (883mg, 1.6mmol) was added to a solution of the compound of Preparation 50 (326mg, 0.81 mmol) in acetonitrile (2.4ml) and water (2.4ml) and the mixture was stirred at room temperature for 5 days, then concentrated under reduced pressure. The residue was dissolved in methanol and adsorbed onto silica gel, then purified by column chromatography on silica gel using an elution gradient of dichloromethane:methanol:0.88 ammonia (100:0:0 to 90:10:1) to afford the title compound as an orange oil, 97mg.
• Ammonium cerium (IV) nitrate (1.43g, 2.61 mmol) was added to a solution of the protected morpholinone of Preparation 74 (330mg, 0.87mmol) in water (2ml) and acetonitrile (2ml), and the mixture was stirred at 40°C for 4 hours. TLC analysis showed starting material remaining, so additional ammonium cerium (IV) nitrate (1.43g, 2.61 mmol) was added, and the mixture was stirred at 40°C for a further 2 hours. The mixture was partitioned between dichloromethane (200ml) and a solution of ethylenediaminetetraacetic acid (1g) in saturated sodium bicarbonate solution (50ml).
• Ammonium cerium (IV) nitrate (297mg, 0.55mmol) was added to a solution of the protected morpholinone of Preparation 75 (94mg, 0.22mmol) in water (2ml) and acetonitrile (2ml), and the mixture was stirred at 40°C for 15 hours.
• Ethylenediaminetetraacetic acid (0.5g) in saturated sodium bicarbonate solution (5ml) was added and the mixture was extracted with dichloromethane (2x50ml). The combined organic extracts were dried (MgS0 4 ) and evaporated under reduced pressure.
• the crude product was purified by column chromatography on silica gel using an elution gradient of ethyl acetate:methanol:diethylamine (98:1 :1 to 94:3:3), to afford the title compound as an oil, 22mg.
• Aryl boronic acids (R-B(OH) 2 ), (0.74mmol) were added to solutions of the bromo compound of Preparation 98 (180mg, 0.49mmol) tetrakis(triphenylphosphine)- palladium(O) (56mg, 0.051 mmol) and sodium carbonate solution (295 ⁇ l, 2M,
• the crude product was pre-adsorbed onto silica gel and purified twice by column chromatography on silica gel using an elution gradient of dichloromethane:methanol:0.88 ammonia (99:1:0.1 to 95:5:0.5) to afford the title compound, 370mg.
• Ammonium cerium (IV) nitrate (482mg, 0.88mmol) and water (1 ml) were added to a solution of the compound of Preparation 60 (181mg, 0.44mmol) in acetonitrile (1 ml) and the mixture was stirred at 40°C for 18 hours. TLC analysis showed starting material remaining, so additional ammonium cerium (IV) nitrate was added (250mg, 0.46mmol) and the mixture was stirred at 40°C for a further 5 hours.
• the mixture was partitioned between dichloromethane (75ml) and a solution of ethylenediaminetetraacetic acid (1g) in aqueous sodium bicarbonate (30ml), and the phases were separated.
• the crude product was purified by column chromatography on silica gel using an elution gradient of dichloromethane: methanol:0.88 ammonia (99:1 :0.1 to 98:2:0.2) to afford the title compound as a white foam, 100mg.
• the residual yellow oil was purified by column chromatography on silica gel using an elution gradient of dichloromethane:methanol:0.88 ammonia (99:1 :0.1 to 98:2:0.2) to afford the title compound as a white foam, 77mg.
• Triethylamine (3ml, 2175mmol) was added dropwise to a solution of the alcohol of Preparation 153 (5.41 g, 14.50mmol) in dichloromethane (60ml), and the solution was cooled to 0°C.
• Methanesulphonyl chloride (1.68ml, 2175mmol) was added, and the mixture was allowed to warm to room temperature, then stirred for a further 2 hours.
• Additional triethylamine (2ml, 14.50mmol) was added, and the mixture was warmed to 35°C, then stirred for 18 hours.
• Ammonium cerium (IV) nitrate (1.1g, 2mmol) was added to a solution of the protected lactam of Preparation 55b (200mg, 0.63mmol) in water (4ml) and acetonitrile (4ml) and the mixture was stirred at room temperature for 3 hours.
• the solution was diluted with acetonitrile (5ml) and 0.88 ammonia (4ml), and the mixture was filtered through Arbocel ® , washing through with a solution of acetonitrile:water (50:50, 10ml). The filtrate was concentrated under reduced pressure and the aqueous residue was washed with ether, then evaporated under reduced pressure.
• the compounds of the present invention may be tested using the following assay, which is based on that disclosed in Boffa et al., J. Biol. Chem. 1998, 273, 2127.
• the compounds are incubated with activated TAFI and a standard substrate for TAFIa, the rate of hydrolysis of the substrate is determined and compared to the rate of hydrolysis in the absence of the compounds, and the amount of inhibition expressed in terms of Kj.
• Human TAFI (recombinant or purified) was activated by incubating 20 ⁇ l of stock solution (360 ⁇ g/ml) with 10 ⁇ l of human thrombin (10NIH units/ml), 10 ⁇ l of rabbit thrombomodulin (30 ⁇ g/ml), 6 ⁇ l calcium chloride (50mM) in 50 ⁇ l of 20mM HEPES (N- [2-hydroxyethyl]piperazine-N-[2-ethanesulfonic acid]) buffer containing 150mM sodium chloride and 0.01% TWEEN 80 (polyoxyethylene-sorbitan monooleate) pH 7.6 for 20 minutes at 22 ° C.
• HEPES N- [2-hydroxyethyl]piperazine-N-[2-ethanesulfonic acid]
• thrombin was neutralised by the addition of 10 ⁇ L of PPACK (D-Phe-Pro-Arg chloromethyl ketone) (1 OOnM).
• PPACK D-Phe-Pro-Arg chloromethyl ketone
• test compound in water A number of different dilutions of the test compound in water were made up. To 20 ⁇ l of each dilution was added 150 ⁇ l of HEPES buffer and 10 ⁇ l of TAFIa, which was then pre-incubated for 15 minutes at 24 e C. To each dilution was then added 20 ⁇ l furylacryloyl-alanyl-lysine (FAAL) at a standard concentration. Substrate turnover was measured by reading the absorbance of the reaction mixture at 330nm every 15 seconds for 30 minutes. The reaction was performed at 24 S C and samples were mixed for 3 seconds prior to each absorbance reading.
• FFAAL furylacryloyl-alanyl-lysine
• the selectivity of the compounds of the present invention for TAFIa over CPN was determined by calculating the Kj of the compounds of the present invention for CPN, then comparing it to the Kj for TAFIa.
• the Kj was calculated using the assay for the calculation of TAFIa Kj, but substituting 10 ⁇ l of human CPN for 10 ⁇ l of TAFIa.
• Those compounds of the present invention tested exhibited a strong selectivity for TAFIa over CPN of the order of >50:1.
• the specific Kj values and calculated selectivities of certain compounds are detailed below:

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Veterinary Medicine (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Cardiology (AREA)
• Biomedical Technology (AREA)
• Heart & Thoracic Surgery (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Surgery (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Dermatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Applications Claiming Priority (5)

Publications (1)

Family

ID=27614792

Family Applications (1)

Country Status (24)

Families Citing this family (10)

Family Cites Families (2)

• 2003
  • 2003-01-10 EP EP03700059A patent/EP1467731A1/en not_active Withdrawn
  • 2003-01-10 EA EA200400716A patent/EA200400716A1/ru unknown
  • 2003-01-10 AP APAP/P/2004/003084A patent/AP2004003084A0/en unknown
  • 2003-01-10 PL PL03371487A patent/PL371487A1/xx unknown
  • 2003-01-10 OA OA1200400190A patent/OA12756A/en unknown
  • 2003-01-10 CA CA002472238A patent/CA2472238A1/en not_active Abandoned
  • 2003-01-10 BR BR0307016-6A patent/BR0307016A/pt not_active IP Right Cessation
  • 2003-01-10 MX MXPA04006573A patent/MXPA04006573A/es unknown
  • 2003-01-10 KR KR10-2004-7011370A patent/KR20040077775A/ko not_active Application Discontinuation
  • 2003-01-10 CN CNA03802599XA patent/CN1620291A/zh active Pending
  • 2003-01-10 WO PCT/IB2003/000060 patent/WO2003061652A1/en not_active Application Discontinuation
  • 2003-01-10 JP JP2003561596A patent/JP2005520811A/ja active Pending
  • 2003-01-10 IL IL16267703A patent/IL162677A0/xx unknown
  • 2003-01-16 TW TW092100889A patent/TW200302094A/zh unknown
  • 2003-01-17 PE PE2003000058A patent/PE20030929A1/es not_active Application Discontinuation
  • 2003-01-20 UY UY27615A patent/UY27615A1/es not_active Application Discontinuation
  • 2003-01-21 AR ARP030100165A patent/AR038197A1/es unknown
  • 2003-01-22 PA PA20038563501A patent/PA8563501A1/es unknown
• 2004
  • 2004-06-14 IS IS7310A patent/IS7310A/is unknown
  • 2004-06-30 TN TNP2004000121A patent/TNSN04121A1/en unknown
  • 2004-07-15 MA MA27786A patent/MA27167A1/fr unknown
  • 2004-07-19 HR HR20040659A patent/HRP20040659A2/hr not_active Application Discontinuation
  • 2004-07-22 EC EC2004005200A patent/ECSP045200A/es unknown
  • 2004-08-19 NO NO20043457A patent/NO20043457L/no not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events